Insider Transactions in Q3 2022 at Zentalis Pharmaceuticals, Inc. (ZNTL)
Insider Transaction List (Q3 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 16
2022
|
Cam Gallagher President, Interim CFO |
SELL
Open market or private sale
|
Direct |
10,000
-1.1%
|
$240,000
$24.68 P/Share
|
|
Sep 15
2022
|
Cam Gallagher President, Interim CFO |
SELL
Open market or private sale
|
Direct |
12,500
-1.35%
|
$312,500
$25.35 P/Share
|
|
Sep 09
2022
|
Jan Skvarka Director |
BUY
Grant, award, or other acquisition
|
Direct |
36,606
+50.0%
|
-
|
|
Aug 10
2022
|
Kevin D. Bunker Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
5,000
-5.0%
|
$150,000
$30.0 P/Share
|
|
Jul 20
2022
|
Kevin D. Bunker Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
5,000
-4.76%
|
$150,000
$30.0 P/Share
|
|
Jul 14
2022
|
Kevin D. Bunker Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
3,290
-3.04%
|
$98,700
$30.01 P/Share
|
|
Jul 13
2022
|
Kevin D. Bunker Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
1,710
-1.55%
|
$51,300
$30.02 P/Share
|
|
Jul 05
2022
|
Kevin D. Bunker Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
25,000
-18.52%
|
$750,000
$30.07 P/Share
|